Lenalidomide in Treating Patients with Castration-Resistant Prostate Cancer

Abstract

<b>Background:</b> This analysis was conducted to evaluate the efficacy and safety of lenalidomide based regimen intreating patients with castration-resistant prostate cancer. Materials and <br/><b>Methods</b>: Clinical studies evaluating theefficacy and safety of lenalidomide based regimens on response and safety for patients with castration-resistantprostate cancer were identified using a predefined search strategy. A pooled response rate (rate of PSA leveldecline of ≥50%) to treatment was calculated. <br/><b>Results</b>: In lenalidomide based regimen, 3 clinical studies whichincluding 98 patients with castration-resistant prostate cancer were considered eligible for inclusion. Theselenalidomide based regimens included cisplatin, doxorubicin, or GM-CSF. Pooled analysis suggested that, inall patients, the pooled PSA level decline of ≥50% was 13.3% (13/98) in lenalidomide based regimens. Fatigue,nausea and vomitting were the main side effects. No grade III or IV renal or liver toxicity were observed. Notreatment related death occurred in patients with lenalidomide based regimens. <br/><b>Conclusions</b>: This evidencebased analysis suggests that lenalidomide based regimens are associated with mild response rate and acceptabletoxicities for treating patients with castration-resistant prostate cancer.